Form 4: Neurocrine Biosciences Executive Stock Sale
Statement of Changes in Beneficial Ownership
Chief Human Resources Officer Julie Cooke exercised stock options and sold shares under a Rule 10b5-1 trading plan.
Summary
- Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, exercised options for 24,965 shares at a price of $81.49.
- Following the exercise, the executive sold a total of 36,937 shares in multiple transactions on June 2, 2026.
- The sales were executed at weighted average prices ranging from $154.8252 to $158.5897 per share.
- The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing related to executive compensation and personal financial planning, carrying no significant signal regarding company performance.
Positives
- The executive maintains a significant remaining stake of 22,374 shares in the company.
- The transactions were pre-planned under a Rule 10b5-1 plan, indicating a structured approach to liquidity rather than reactive selling.
Negatives
- The filing reflects a net reduction in the executive's direct beneficial ownership of company stock.
Risks
- The executive is restricted by company policy from amending or modifying the 10b5-1 trading plan once adopted.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal financial portfolios and is generally viewed as neutral by the market.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for biotech executives to avoid potential conflicts of interest regarding material non-public information.
Stakeholder Impact
- Minimal impact on shareholders as the sales were conducted through a pre-arranged, automated trading plan.
Next Steps
- None mentioned.
Key Dates
| Date | Description |
|---|---|
| 02/05/2018 | Original grant date of the stock options. |
| 03/03/2026 | Date the Rule 10b5-1 trading plan was adopted. |
| 06/02/2026 | Date of the option exercise and subsequent share sales. |
Keywords
Neurocrine Biosciences, NBIX, Insider Trading, Form 4, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.